Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Bevacizumab (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Therapeutic Use
- 19 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 Aug 2018.
- 05 Dec 2017 Results published in a Genentech Media Release.
- 05 Dec 2017 According to a Genentech media release, company announced that U.S. Food and Drug Administration (FDA) has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy, based on the data from this study.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History